CYH33 (Figure 2) is a PI3Kα inhibitor that demonstrates an objective response rate (ORR) of 14.3% in the treatment of solid tumors harboring PIK3CA mutations, including HNSCC (NCT03544905) [19]. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.